<?xml version="1.0" encoding="UTF-8"?>
<p>LAIVs have been used in Russia since the 1960s and were licensed for use in North America and Europe in 2003 [
 <xref rid="B4-antibodies-09-00020" ref-type="bibr">4</xref>]. Recently, Russian LAIVs were licensed in China (
 <uri xlink:href="http://www.biodiem.com/wp-content/uploads/2020/02/20-02-28-LAIV-influenza-vaccine-approved-in-China.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.biodiem.com/wp-content/uploads/2020/02/20-02-28-LAIV-influenza-vaccine-approved-in-China.pdf</uri>). The efficacy of intranasal LAIVs is up to 80% in children under six years of age, and 40% in adults [
 <xref rid="B5-antibodies-09-00020" ref-type="bibr">5</xref>,
 <xref rid="B6-antibodies-09-00020" ref-type="bibr">6</xref>].
</p>
